MYO1G

Across TCGA pan-cancer cohorts, MYO1G mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO1G data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MYO1G mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO1G expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, GBM, and LSCC are the cancer types where MYO1G mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.859	1.000	.024	24	view →
GBM	OS	Tertile	All	0.369	0.703	.003	7	view →
LSCC	DFS	Median	II,III,IV	0.551	0.846	.015	4	view →
LUAD	OS	Median	III,IV	0.750	0.998	.025	3	view →
PDAC	OS	Quartile	All	0.679	0.370	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYO1G–COAD (DFS)

Open the COAD breakdown →